KISSEI PHARMACEUTICAL CO chart

Last update: 2021-02-19
Key statistics and financials
Revenue per share 1,410.19
Dividend & Yield80.00¥ (3.27%)
Beta 0.38
Market capitalization 110.22B
Operating cash flow N/A
ESG Scores unknown

Company description

Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial data

Financial Statements

Cashflow Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Change To Liabilities -546M 890M 2.67B -3.8B
Total Cashflows From Investing Activities -2.09B 490M -9.33B 10.78B
Net Borrowings 61M -1.93B -16M -103M
Total Cash From Financing Activities -2.31B -4.42B -4B -2.76B
Change To Operating Activities -2.8B 389M -77M 2.52B
Issuance Of Stock
Net Income 5.48B 2.82B 5.29B 12.92B
Change In Cash 1.95B 10B -15.87B 9.56B
Effect Of Exchange Rate 1M 4M 4M 4M
Total Cash From Operating Activities 6.35B 13.93B -2.54B 1.53B
Depreciation 2.61B 2.56B 3.15B 3.73B
Change To Account Receivables 1.91B 7.5B -3.6B 250M
Other Cashflows From Financing Activities -78M -103M -206M -117M
Change To Netincome -3.91B -2.56B -5.49B -18.8B
Capital Expenditures -1.09B -879M -931M -1.49B

Income Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Research Development 15.71B 10.77B 9.63B 10.36B
Income Before Tax 7.12B 4.63B 7.48B 16.51B
Net Income 5.48B 2.82B 5.29B 12.92B
Selling General Administrative 22.58B 21.13B 19.61B 19.92B
Gross Profit 45.57B 34.91B 32.72B 31.24B
Ebit 6.2B 1.86B 1.51B -1.4B
Operating Income 6.2B 1.86B 1.51B -1.4B
Interest Expense -23M -23M -23M -23M
Income Tax Expense 1.59B 1.74B 2.1B 3.48B
Total Revenue 72.3B 63.23B 69.04B 65.38B
Cost Of Revenue 26.73B 28.33B 36.32B 34.14B
Total Other Income ExpenseNet 917M 2.77B 5.97B 17.91B
Net Income From Continuing Ops 5.54B 2.89B 5.38B 13.03B
Net Income Applicable To Common Shares 5.48B 2.82B 5.29B 12.92B

Balance Sheet Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Total Liabilities 30.82B 38.83B 48.91B 35.91B
Total Stockholder Equity 182.26B 192.46B 219.31B 201.38B
Other Current Liabilities 5.7B 8.18B 6.76B 11.28B
Total Assets 213.52B 231.79B 268.86B 238.09B
Common Stock 24.36B 24.36B 24.36B 24.36B
Other Current Assets 5.49B 4.11B 5.33B 5.25B
Retained Earnings 106.03B 106.46B 109.27B 118.18B
Treasury Stock 27.65B 37.42B 61.46B 34.62B
Cash 26.32B 36.33B 20.46B 30.01B
Total Current Liabilities 13.8B 17.02B 18.25B 18.74B
Other Stockholder Equity 39.26B 49.03B 74.37B 47.53B
Property, Plant, and Equipment 25.5B 24.61B 24.29B 24.07B
Total Current Assets 95.78B 96.68B 92.97B 99.34B
Net Tangible Assets 180.74B 190.95B 217.67B 199.82B
Net Receivables 26.96B 19.46B 23.06B 21.96B
Accounts Payable 4.35B 5.24B 7.91B 4.1B


Insider Transactions

Here are the insider transactions of stock shares related to KISSEI PHARMACEUTICAL CO:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to KISSEI PHARMACEUTICAL CO. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on KISSEI PHARMACEUTICAL CO

Here is the result of two systematic investment strategies applied to KISSEI PHARMACEUTICAL CO. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on KISSEI PHARMACEUTICAL CO

The following chart shows the equity curve of the two systematic investment strategies applied to KISSEI PHARMACEUTICAL CO:

KISSEI PHARMACEUTICAL CO automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -24.45% on the backtest period.

Performance at glance

Performance

-24.45 %

Latent gain

-2918.0 ¥

Invested capital

11934.0 ¥

Annualized return

-5.82 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on KISSEI PHARMACEUTICAL CO

This is the result of two momentum investment strategies applied to KISSEI PHARMACEUTICAL CO. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on KISSEI PHARMACEUTICAL CO

The following chart shows all the entries opened by the momentum investment system on KISSEI PHARMACEUTICAL CO:

KISSEI PHARMACEUTICAL CO momentum entries
  • The first momentum investment strategy would give -21.34% of return on KISSEI PHARMACEUTICAL CO. That represents -1835.0¥ of latent gain with 8597.0¥ of employed capital.
  • The second momentum investment strategy would give -22.69% of return on KISSEI PHARMACEUTICAL CO. That represents -1985.0¥ of latent gain with 8747.0¥ of employed capital.
Performance at glance (1Q Momentum)

Performance

-21.34 %

Latent gain

-1835.0 ¥

Invested capital

8597.0 ¥

Annualized return

-9.33 %
Performance at glance (2Q Momentum)

Performance

-22.69 %

Latent gain

-1985.0 ¥

Invested capital

8747.0 ¥

Annualized return

-6.1 %

Momentum equity curve on KISSEI PHARMACEUTICAL CO

The following chart shows the equity curve of the two momentum strategies applied to KISSEI PHARMACEUTICAL CO:

KISSEI PHARMACEUTICAL CO momentum equity

Note: the dividends potentially given by KISSEI PHARMACEUTICAL CO are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on KISSEI PHARMACEUTICAL CO

The following chart shows the employed capital evolution of the two momentum strategies on KISSEI PHARMACEUTICAL CO since the beginning:

KISSEI PHARMACEUTICAL CO

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250¥, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000¥.


Buy the dip strategy result on KISSEI PHARMACEUTICAL CO

Buy the dip entry openings on KISSEI PHARMACEUTICAL CO

KISSEI PHARMACEUTICAL CO

The performance achieved by the robo-advisor on KISSEI PHARMACEUTICAL CO is -20.52%. That represents -1746.0$ of latent gain with 8508.0¥ of employed capital. The following chart shows KISSEI PHARMACEUTICAL CO stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of KISSEI PHARMACEUTICAL CO, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-20.52 %

Latent gain

-1746.0 ¥

Invested capital

8508.0 ¥

Annualized return

-9.33 %

Equity curve of the strategy applied to KISSEI PHARMACEUTICAL CO

The following chart shows the result of the investment strategy applied to KISSEI PHARMACEUTICAL CO:

KISSEI PHARMACEUTICAL CO

Note: the dividends potentially given by KISSEI PHARMACEUTICAL CO are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on KISSEI PHARMACEUTICAL CO

The following chart shows the employed capital evolution since the beginning of the investment strategy on KISSEI PHARMACEUTICAL CO:

KISSEI PHARMACEUTICAL CO

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on KISSEI PHARMACEUTICAL CO

In this section, I will compare the three previous investment strategies applied to KISSEI PHARMACEUTICAL CO.

Equity curve comparison on KISSEI PHARMACEUTICAL CO

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

KISSEI PHARMACEUTICAL CO investment strategy comparison

Employed capital comparison on KISSEI PHARMACEUTICAL CO

KISSEI PHARMACEUTICAL CO investment comparison

Performance comparison on KISSEI PHARMACEUTICAL CO

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -24.45% -2918.0¥ 11934.0¥ -5.82%
Momentum 1 quarter -21.34% -1835.0¥ 8597.0¥ -5.39%
Momentum 2 quarters -22.69% -1985.0¥ 8747.0¥ -6.1%
Non-directional -20.52% -1746.0¥ 8508.0¥ -9.33%
Annualized return comparison

Automatic investment

-5.82 %

Momentum 1Q

-6.1 %

Momentum 2Q

-6.1 %

Non-directional

-9.33 %

Correlated stocks

Here are the most positively and negatively correlated stocks with KISSEI PHARMACEUTICAL CO:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between KISSEI PHARMACEUTICAL CO and the other stocks. There may be false positives or some missing correlated stocks. If the price of KISSEI PHARMACEUTICAL CO does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name KISSEI PHARMACEUTICAL CO
Country Japan
City Matsumoto
Address 19-48, Yoshino
Phone 81 263 25 9081
Website www.kissei.co.jp
FullTime employees 1828
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
Exchange XTKS
Ticker 4547.XTKS
Market www.jpx.co.jp

KISSEI PHARMACEUTICAL CO ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown